Clinical trial of ABCB5(+) mesenchymal stem cells for recessive dystrophic epidermolysis bullosa

BACKGROUND: Recessive dystrophic epidermolysis bullosa (RDEB) is a rare, devastating, and life-threatening inherited skin fragility disorder that comes about due to a lack of functional type VII collagen, for which no effective therapy exists. ABCB5(+) dermal mesenchymal stem cells (ABCB5(+) MSCs) p...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiritsi, Dimitra, Dieter, Kathrin, Niebergall-Roth, Elke, Fluhr, Silvia, Daniele, Cristina, Esterlechner, Jasmina, Sadeghi, Samar, Ballikaya, Seda, Erdinger, Leoni, Schauer, Franziska, Gewert, Stella, Laimer, Martin, Bauer, Johann W., Hovnanian, Alain, Zambruno, Giovanna, El Hachem, May, Bourrat, Emmanuelle, Papanikolaou, Maria, Petrof, Gabriela, Kitzmüller, Sophie, Ebens, Christen L., Frank, Markus H., Frank, Natasha Y., Ganss, Christoph, Martinez, Anna E., McGrath, John A., Tolar, Jakub, Kluth, Mark A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8663784/
https://www.ncbi.nlm.nih.gov/pubmed/34665781
http://dx.doi.org/10.1172/jci.insight.151922

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8663784/
https://www.ncbi.nlm.nih.gov/pubmed/34665781
http://dx.doi.org/10.1172/jci.insight.151922

Ejemplares similares